Similar articles for PMID: 22485250

Year	Number of Results
1994	1
1995	1
1996	2
1997	1
1998	1
1999	4
2000	2
2001	5
2002	4
2003	5
2004	5
2005	5
2006	8
2007	6
2008	4
2009	7
2010	6
2011	11
2012	7
2013	13
2014	8
2015	3
2016	3
2017	1
2018	5
2019	7
2020	5
2021	2
2022	2
2023	1
2024	0

1

ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.

Teixidó C, Arguelaguet E, Pons B, Aracil M, Jimeno J, Somoza R, Marés R, Ramón Y Cajal S, Hernández-Losa J. Teixidó C, et al. Int J Oncol. 2012 Jul;41(1):317-24. doi: 10.3892/ijo.2012.1425. Epub 2012 Apr 3. Int J Oncol. 2012. PMID: 22485250

2

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.

Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E. Serova M, et al. Mar Drugs. 2013 Mar 20;11(3):944-59. doi: 10.3390/md11030944. Mar Drugs. 2013. PMID: 23519149 Free PMC article.

3

Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.

Ling YH, Aracil M, Jimeno J, Perez-Soler R, Zou Y. Ling YH, et al. Eur J Cancer. 2009 Jul;45(10):1855-64. doi: 10.1016/j.ejca.2009.03.003. Epub 2009 Apr 5. Eur J Cancer. 2009. PMID: 19346126 Free PMC article.

4

Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines.

Teixidó C, Marés R, Aracil M, Ramón y Cajal S, Hernández-Losa J. Teixidó C, et al. PLoS One. 2013;8(1):e53645. doi: 10.1371/journal.pone.0053645. Epub 2013 Jan 8. PLoS One. 2013. PMID: 23320098 Free PMC article. Retracted.

5

Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.

Yotsumoto F, Fukami T, Yagi H, Funakoshi A, Yoshizato T, Kuroki M, Miyamoto S. Yotsumoto F, et al. Cancer Sci. 2010 Nov;101(11):2351-60. doi: 10.1111/j.1349-7006.2010.01671.x. Cancer Sci. 2010. PMID: 20726858 Free article.

6

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B. Wang S, et al. Breast Cancer Res. 2013;15(5):R101. doi: 10.1186/bcr3563. Breast Cancer Res. 2013. PMID: 24168763 Free PMC article.

7

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA. Camblin AJ, et al. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16. Clin Cancer Res. 2018. PMID: 29549161

8

ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment.

Váradi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, Galmarini CM, Szöllosi J, Nagy P. Váradi T, et al. Eur J Pharmacol. 2011 Sep 30;667(1-3):91-9. doi: 10.1016/j.ejphar.2011.05.064. Epub 2011 Jun 2. Eur J Pharmacol. 2011. PMID: 21658382

9

Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling.

Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA, Giaccone G. Janmaat ML, et al. Mol Pharmacol. 2005 Aug;68(2):502-10. doi: 10.1124/mol.105.011361. Epub 2005 May 20. Mol Pharmacol. 2005. PMID: 15908515

10

Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC. Bunn PA Jr, et al. Clin Cancer Res. 2001 Oct;7(10):3239-50. Clin Cancer Res. 2001. PMID: 11595720

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

125 results

Results by year